SCHEMBL2336847

SCHEMBL2336847

CC(C)NC1CCC(Oc2ccc3c(=O)[nH]ccc3c2)CC1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 15/20 0.65
ROCK2 O75116 6/20 0.65
PRKCD Q05655 2/20 0.65
PRKACA P17612 1/20 0.65
PRKG1 Q13976 1/20 0.65
PKN1 Q16512 1/20 0.65
PKN2 Q16513 1/20 0.65
AAK1 Q2M2I8 1/20 0.65
CDC42BPA Q5VT25 1/20 0.65
Q6ZSR9 Q6ZSR9 1/20 0.65
BMP2K Q9NSY1 1/20 0.65
CDC42BPB Q9Y5S2 1/20 0.65
PRKX P51817 1/20 0.60
PRKCE Q02156 1/20 0.60
PRKD1 Q15139 1/20 0.60
MAP2K1 Q02750 1/20 0.46
HRH3 Q9Y5N1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2336851 1.00 ROCK1 (0.65) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL1205053 0.88 ROCK1 (0.70) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL1205052 0.88 ROCK1 (0.70) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL12211977 0.86 ROCK1 (0.64) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL2340471 0.84 ROCK1 (0.80) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL2340474 0.84 ROCK1 (0.80) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL2336624 0.82 ROCK1 (0.63) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL2336621 0.82 ROCK1 (0.63) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL4075892 0.81 ROCK1 (0.65) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL4075896 0.81 ROCK1 (0.65) ROCK1ROCK2PRKCDPRKACAPRKG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796458-B2 Cyclohexylamine isoquinolone derivatives SANOFI (FR) 2014-08-05 US disclosed
US-8609691-B2 Cyclohexylamin isoquinolone derivatives SANOFI (FR) 2013-12-17 US disclosed
US-20110251226-A1 CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES SANOFI-AVENTIS (FR) 2011-10-13 US disclosed
EP-1912949-B1 CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS SANOFI SA (FR) 2011-08-24 EP disclosed
US-20080242699-A1 Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one SANOFI-AVENTIS (FR) 2008-10-02 US disclosed
EP-1912949-A1 CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS Sanofi-Aventis (FR) 2008-04-23 EP disclosed
WO-2007012422-A1 CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS SANOFI-AVENTIS (DE) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242699-A1 Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one MYLK, MYLK2, ROCK1 ROCK1 3/4885ROCK2 5/4885PRKCD 282/4885
US-20110251226-A1 CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES MYLK2, MYLK, MYLK3 ROCK1 7/4885ROCK2 10/4885PRKCD 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.